NEW YORK (GenomeWeb News) – Sequenom's former senior vice president of research and develop has pled guilty to a charge that she made false statements about the company's prenatal test for Down syndrome and will be sentenced on Aug. 30, the firm disclosed in a document filed with the US Securities and Exchange Commission after the close of the market on Tuesday.